Since its approval, the drug, developed by Eli Lilly and Company, has become one of the preferred treatments for patients with RET gene mutations. Selpercatinib has won wide recognition from clinicians and patients for its high efficacy. So, is the treatment of Selpercatinib(Retevmo) good?

The treatment effect of Selpercatinib(Retevmo)

Selpercatinib is an important therapeutic drug, and its therapeutic effect has been fully verified in multiple clinical trials, as follows:

Obvious effect on the treatment of lung diseases

Selpercatinib has shown good therapeutic efficacy in the treatment of non-small cell lung diseases, especially in patients with RET gene fusions. Clinical trials have shown that patients treated with Selpercatinib have a significant reduction in lesional cell burden and a larger proportion of lesional cell shrinkage.

Excellent treatment effect of thyroid disease

Selpercatinib is also excellent in the treatment of thyroid disease. For patients with thyroid disease who are positive for RET gene fusion, Selpercatinib can inhibit the growth of diseased cells, slow down the deterioration of the disease, and significantly improve the survival rate of patients. For patients with previously treated thyroid disease, Selpercatinib also showed good anti-lesional cell activity and tolerability.

Selpercatinib has demonstrated good and durable efficacy in the treatment of both non-small cell lung disease and thyroid disease, providing a new treatment option for these patients. The effect of treatment varies from patient to patient, and the specific use should be guided by a doctor.

Selpercatinib(Retevmo)'s usage in special populations

Selpercatinib is a highly selective RET kinase inhibitor for special populations, and the following are some detailed precautions:

Pediatric patients

The effectiveness of Selpercatinib in patients younger than 12 years of age has not been fully validated. In this age group, Selpercatinib requires extreme caution. For patients 12 years of age and older, Selpercatinib has been approved for the treatment of specific types of disease, but doctors should carefully plan treatment with a case-by-case assessment of the risks and benefits.

Seniors

Although there is no significant difference in effectiveness between older and younger people, due to the complexity of the elderly's own condition, such as possible decline in liver and kidney function, it is recommended to use Selpercatinib under the guidance of a doctor. Doctors should consider the patient's overall health, other medical conditions, and other medications being used to develop the most appropriate treatment plan.

When using Selpercatinib, special populations should pay special attention to the above matters and individualize treatment under the guidance of a doctor. Patients should monitor the relevant indicators regularly to ensure the effectiveness of treatment and reduce side effects.